Medical imaging solutions provider VirtualScopics Inc. (VSCP) has reportedly joined forces with Germany-based full-service contract research organization (CRO) ABX-CRO. This marks the union of two of the bellwethers in molecular imaging for the clinical trials of drugs and medical devices.
The collaboration will focus on offering integrated solutions to pharmaceutical and medical devices customers, leveraging the combined experience and complementary expertise in functional medical imaging techniques, notably, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). As such, the clients will be able the source the best-in-class solutions and capitalize on the capabilities of functional imaging in drug and medical devices development.
VirtualScopics offers its imaging solutions to pharmaceutical, biotechnology and medical device industries. The company provides a range of imaging software and applications that are being used for image-based detection and measurement of anatomical structures and metabolic activity.
The company swung to profit in the second quarter of fiscal 2010 on the back of solid top-line growth, boosted by increased demand for its services across novel therapeutic markets (including medical devices).
VirtualScopics remains committed to investing in infrastructure, services and additional technical and operational resources to address customer needs and broaden its global foothold. The company opened an office in central Europe in August 2010, which will focus on its thriving international customer base and explore business opportunities in Europe.
ABX-CRO (established in 2002) offers drug development services in nuclear medicine, with a special emphasis on oncology, neuroscience and diagnostic imaging. The entity is focused on developing PET and SPECT tracers, stand-alone PET/SPECT imaging solutions for clinical trials and pharmacological imaging solutions.
The pooling of VirtualScopics’ image acquisition and analysis package with ABX-CRO’s tracer technology is expected to boost the use of molecular imaging in the development of drugs and medical devices.
